anti-Solute Carrier Family 16, Member 1 (Monocarboxylic Acid Transporter 1) (SLC16A1) Antibodies

Human Solute Carrier Family 16, Member 1 (Monocarboxylic Acid Transporter 1) (SLC16A1) interaction partners

1. Metabolism-dependent clonal growth of HCT15 colorectal cancer cells was induced by Nrf2 (show GABPA Antibodies)-dependent activation of MCT1 (show CMA1 Antibodies)-driven lactate exchange.

2. Using in vitro models, we demonstrate that tumor-excreted branched-chain amino acid (BCKA)s can be taken up and re-aminated to BCAAs by tumor-associated macrophages. Our data further suggest that the anti-proliferative effects of MCT1 (show CMA1 Antibodies) knockdown observed by others might be related to the blocked excretion of BCKAs.

3. Study demonstrated that the high mRNA level of both MCT1 (show CMA1 Antibodies) and GLUT1 (show SLC2A1 Antibodies) correlated with poor prognosis, high- Fuhrman grade clear-cell renal cell carcinoma (show MOK Antibodies) and metabolic reprogramming.

4. Hypoxia-induced MCT1 (show CMA1 Antibodies) supports glioblastoma glycolytic phenotype, being responsible for lactate efflux and an important mediator of cell survival and aggressiveness

5. our finding that the expression of MCT1 (show CMA1 Antibodies) and MCT4 (show SLC16A4 Antibodies) is reduced in mutant IDH1 (show IDH1 Antibodies) gliomas highlights the unusual metabolic reprogramming that occurs in mutant IDH1 (show IDH1 Antibodies) tumors and has important implications for our understanding of these tumors and their treatment

6. MCT1 (show CMA1 Antibodies) expression, independent of transporter activity, is required for growth factor-induced tumor cell motility.

7. TOMM20 (show TOMM20 Antibodies), MCT1 (show CMA1 Antibodies), and MCT4 (show SLC16A4 Antibodies) expression was significantly different in Hodgkin and Reed Sternberg (HRS) cells. HRS have high expression of MCT1 (show CMA1 Antibodies), while tumor associated macrophages have absent MCT1 (show CMA1 Antibodies) expression. Tumor-infiltrating lymphocytes have absent MCT1 (show CMA1 Antibodies) expression. Reactive lymph nodes in contrast to cHL (show CHRDL1 Antibodies) tumors had low TOMM20 (show TOMM20 Antibodies), MCT1 (show CMA1 Antibodies), and MCT4 (show SLC16A4 Antibodies) expression in lymphocytes and macrophages.

8. TOMM20 (show TOMM20 Antibodies) and MCT1 (show CMA1 Antibodies) were highly expressed in diffuse large B-cell lymphoma lymphocytes, indicating an OXPHOS phenotype, whereas non-neoplastic lymphocytes in the control samples did not express these markers.

9. MCT1 (show CMA1 Antibodies) inhibitor AZD3965 increased MCT4 (show SLC16A4 Antibodies)-dependent accumulation of intracellular lactate, inhibiting monocarboxylate influx and efflux.

10. Silencing or genetic deletion of MCT1 (show CMA1 Antibodies) in vivo inhibited migration, invasion, and spontaneous metastasis.

Zebrafish Solute Carrier Family 16, Member 1 (Monocarboxylic Acid Transporter 1) (SLC16A1) interaction partners

1. Data indicate that monocarboxylate transporters (MCTs1 (show MCTS1 Antibodies)-4) were all found to be expressed in brains of embryos, and were localized in both neurons and astrocyte.

Horse (Equine) Solute Carrier Family 16, Member 1 (Monocarboxylic Acid Transporter 1) (SLC16A1) interaction partners

1. The expression of monocarboxylic acid transporter 1 (MCT1 (show MCTS1 Antibodies)), MCT2 (show SLC16A7 Antibodies), and CD147 in 3 horse breeds with different atheletic demands is reported.[MCT1 (show MCTS1 Antibodies); MCT2 (show SLC16A7 Antibodies)]

2. Results indicated that a single IET resulted in transient increases in MCT1 (show MCTS1 Antibodies) and MCT4 (show SLC16A3 Antibodies) mRNA expression and protein content in untrained and trained horses.

3. The coding sequence of MCT1 (show MCTS1 Antibodies), MCT4 (show SLC16A3 Antibodies), and CD147 in healthy horses, and the incidence of polymorphisms of these proteins in horses with excercise-induced myopathy are reported.

4. MCT1 (show MCTS1 Antibodies) protein content in GMM samples obtained when the horses were 24 months old was significantly higher than at 2 months of age. However, MCT4 (show SLC16A3 Antibodies) protein content remained unchanged throughout the study period.

Mouse (Murine) Solute Carrier Family 16, Member 1 (Monocarboxylic Acid Transporter 1) (SLC16A1) interaction partners

1. Silencing or genetic deletion of MCT1 (show MCTS1 Antibodies) in vivo inhibited migration, invasion, and spontaneous metastasis.

2. It was concluded that both MCT1 (show MCTS1 Antibodies) and CAII (show CA2 Antibodies) are involved in the homeostatic control of pH in skeletal muscle, both at rest and at the onset of exercise. The improved muscle function and resistance to fatigue in MCT1 (show MCTS1 Antibodies)(+/-) mice remain unexplained.

3. Exercise-induced changes in tumour LDH-B (show LDHB Antibodies) and MCT1 (show MCTS1 Antibodies) expression are modulated by oestrogen-related receptor alpha in breast cancer-bearing BALB/c mice

4. Chronic lactate administration after exercise increases MCT1 (show MCTS1 Antibodies) protein expression, which can be involved in the regulation of the observed increase in muscle glycogen (show GYS1 Antibodies) storage after exercise training.

5. This study showed that mouse MCT1 (show MCTS1 Antibodies), MCT2 (show SLC16A7 Antibodies), and MCT4 (show SLC16A3 Antibodies) are expressed in the PNS. While DRG neurons express MCT1 (show MCTS1 Antibodies), myelinating Schwann cells.

6. These data for the first time demonstrate that MCT1 (show MCTS1 Antibodies) is critical for regeneration of both sensory and motor axons in mice following sciatic nerve crush

7. in Parkinson's disease, the levels of MCT1 (show MCTS1 Antibodies), MCT2 (show SLC16A7 Antibodies) and GLUT1 (show SLC2A1 Antibodies) is not changed following dopaminergic neurodegeneration

8. results suggest that a reduction in mitochondria is a result, rather than the cause, of the metabolic deficiency observed in Basigin-null mice, and likely occurs because of reduced metabolic activity in the absence of MCT1 (show MCTS1 Antibodies) expression.

9. miR (show MLXIP Antibodies)-29a, miR (show MLXIP Antibodies)-29b selectively target MCT1 (show MCTS1 Antibodies) 3'UTR (show UTS2R Antibodies) ; the miR (show MLXIP Antibodies)-29 isoforms are highly expressed in islets and contribute to silencing Mct1 (show MCTS1 Antibodies) in beta cells; miR (show MLXIP Antibodies)-29 isoforms contribute to beta-cell-specific silencing of the MCT1 (show MCTS1 Antibodies) transporter and may affect insulin (show INS Antibodies) release

10. monocarboxylate transporter 1 (MCT1), is highly enriched within oligodendroglia and disruption of this transporter produces axon damage and neuron loss in animal and cell culture models; in addition, this same transporter is reduced in patients with, and in mouse models of, amyotrophic lateral sclerosis, suggesting a role for oligodendroglial MCT1 (show MCTS1 Antibodies) in pathogenesis

Cow (Bovine) Solute Carrier Family 16, Member 1 (Monocarboxylic Acid Transporter 1) (SLC16A1) interaction partners

1. This study confirmed age-dependent changes of MCT1 (show MCTS1 Antibodies) expression in the rumen epithelium of newborn calves and showed that its expression might be affected by liquid feed type.

2. These findings show that MCT 1 (show MCTS1 Antibodies) increases with the development of rumen function and also in adult animals MCT 1 (show MCTS1 Antibodies) may change with the feeding.

3. The expression and distribution of monocarboxylate transporter 1 along the gastrointestinal tract of calves suggest it may play a role in transport of short chain fatty acids and their metabolites.

4. The results show that monocarboxylate transporter 1 (MCT1) is a major route for short chain fatty acids (SCFA) efflux across the basolateral membrane of bovine large intestine and that it could play a role in the regulation of intracellular pH.